Pros and cons of different therapeutic antibody formats for recombinant antivenom development
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many advances in immunology, synthetic biology, and antibody research, different approaches and antibody formats are being investigated for the ability to neutralize animal toxins. These different molecular formats each have their own therapeutic characteristics. In this review, we provide an overview of the advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic features, propensity to cause adverse reactions, formulation, and expression for research and development (R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the use of human antibody formats as well as camelid heavy-domain antibody fragments due to their compatibility with the human immune system, beneficial therapeutic properties, and the ability to manufacture these molecules cost-effectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032 · cited 1×
“For production of therapeutic antibodies, mammalian cell lines are often chosen as the expression organism (Berlec and Strukelj, 2013; Wurm, 2004).”
BackgroundEffects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
Boswell, C. A., Tesar, D. B., Mukhyala, K., Theil, F.-P., Fielder, P. J., & Khawli, L. A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100261d · Cited by 398
Raghavan, M., Bonagura, V. R., Morrison, S. L., & Bjorkman, P. J. (1995) · Biochemistry · doi:10.1021/bi00045a005 · Cited by 317
Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications
Tiede, C., Tang, A. A. S., Deacon, S. E., Mandal, U., Nettleship, J. E., Owen, R. L., George, S. E., Harrison, D. J., Owens, R. J., Tomlinson, D. C., et al. (2014) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzu007 · Cited by 163
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli
Gaciarz, A., Veijola, J., Uchida, Y., Saaranen, M. J., Wang, C., Hörkkö, S., & Ruddock, L. W. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0419-5 · Cited by 100
Cited by
Muyldermans, S. (2021) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-021419-083831 · Cited by 338
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Bates, A., & Power, C. A. (2019) · Antibodies · doi:10.3390/antib8020028 · Cited by 237
Bittenbinder, M. A., van Thiel, J., Cardoso, F. C., Casewell, N. R., Gutiérrez, J.-M., Kool, J., & Vonk, F. J. (2024) · Communications Biology · doi:10.1038/s42003-024-06019-6 · Cited by 132
Self-citationSnake Antivenoms—Toward Better Understanding of the Administration Route
Gamulin, E., Mateljak Lukačević, S., Halassy, B., & Kurtović, T. (2023) · Toxins · doi:10.3390/toxins15060398 · Cited by 30
Campos Farias, B. J., Makoto Kayano, A., Barros Luiz, M., Maciel DE Lima, A., Suelen da Silva Morais, M., Moreira Mendes, L., Mota Santana, H., Reis Prado, N. D., Andrade Roberto, S., Martins Soares, A., et al. (2024) · Toxicon · doi:10.1016/j.toxicon.2024.107837 · Cited by 1
Metadata
- Authors
- Laustsen, A. H., María Gutiérrez, J., Knudsen, C., Johansen, K. H., Bermúdez-Méndez, E., Cerni, F. A., Jürgensen, J. A., Ledsgaard, L., Martos-Esteban, A., Øhlenschlæger, M., Pus, U., Andersen, M. R., Lomonte, B., Engmark, M., & Pucca, M. B.
- Venue
- Toxicon
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 146
- Pages
- 151-175
- ISSN
- 0041-0101 (ISSN-L)
- OpenAlex
- W2789977408
- Cited by
- 177
- References
- 12
- FWCI
- 11.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pros and cons of different therapeutic antibody formats for recombinant antivenom development. https://app.cochat.ai/papers/10.1016/j.toxicon.2018.03.004
- The paper
- Laustsen, A. H., María Gutiérrez, J., Knudsen, C., Johansen, K. H., Bermúdez-Méndez, E., Cerni, F. A., Jürgensen, J. A., Ledsgaard, L., Martos-Esteban, A., Øhlenschlæger, M., Pus, U., Andersen, M. R., Lomonte, B., Engmark, M., & Pucca, M. B. (2018). Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon. https://doi.org/10.1016/j.toxicon.2018.03.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.